NDAINTRAVENOUSSOLUTION
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BLOXIVERZ (neostigmine methylsulfate) by Sagent Pharmaceuticals is inhibitor. First approved in 2013.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLOXIVERZ (neostigmine methylsulfate) is an intravenous acetylcholinesterase inhibitor that reverses nondepolarizing neuromuscular blockade by increasing acetylcholine in the synaptic cleft. It is used in perioperative settings to antagonize neuromuscular blocking agents after anesthesia. The drug restores neuromuscular function in patients recovering from surgery.
Peak
Product is in peak commercial phase with moderate competitive pressure (30%), suggesting stable revenue but potential for erosion as competitors strengthen market presence.
Mechanism of Action
inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BLOXIVERZ offers limited career advancement given zero linked job openings and peak-stage commercialization with no pipeline expansion. Roles are primarily focused on maintaining market share in a niche perioperative segment rather than driving growth initiatives.
Brand Manager
Worked on BLOXIVERZ at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.